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dominated vemurafenib. For sensitivity analysis, 95% of the variance was accounted 
for by health state utilities and cost of dabrafenib. ConClusions: Dabrafenib is the 
most cost-effective treatment for metastatic melanoma in patients with BRAFV600 
mutation given our assumptions. Given the similar QALYs and side effects profile of 
dabrafenib and vemurafenib, but higher drug cost of vemurafenib, a 25% price reduc-
tion for vemurafenib could bring this drug into the cost-effective range. A specific 
decrease of 63% in utility of progression on dabrafenib or a minimum decrease of 
28% for utility of stable disease on dabrafenib is needed to make vemurafenib the 
most cost-effective option.
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objeCtives: To evaluate the cost-effectiveness of afatinib, erlotinib, and cis-
platin/pemetrexed chemotherapy, for first-line treatment of metastatic EGFR-
mutation positive non-small cell lung cancer (NSCLC). Methods: A Markov 
model simulated the lifetime progression of EGFR-mutation positive stage IIIB/
IV NSCLC patients, under each treatment option, from a US societal perspective. 
Probabilities, survival rates and health utilities were obtained from clinical trials 
(LUX-3, LUX-6, EURTAC and OPTIMAL) and published literature. Progression-free 
and overall survival in the erlotinib trial were adjusted up to account for differ-
ences in poorer ECOG performance status compared to the afatinib trial. Costs 
included those for drugs, progression, and side effects in 2013 USD. Expected 
QALYS were calculated. The impact of varying parameters on model outcomes 
was examined using probabilistic sensitivity analyses. Results: In the base-case 
model, treatment with afatinib was least expensive, with lifetime cost of $38,406, 
followed by cisplatin/pemetrexed ($40,714), and erlotinib ($41,344). Survival was 
highest with erlotinib (5.27 quality-adjusted life-months saved [QALMS]), followed 
by afatinib (4.02 QALMS), and cisplatin/pemetrexed (3.51 QALMS). Compared 
to erlotinib, afatinib had lower monthly drug costs ($5,648 versus $5,853), but 
higher overall side effects costs ($3,669 versus $1,690). Cisplatin/pemetrexed 
was dominated by afatinib. Erlotinib was cost-effective compared with afatinib 
(ICER= $28,210/QALYS). In a model without survival adjustments, afatinib com-
pared with erlotinib had an ICER over the WTP threshold (ICER= $542,745/QALYS), 
with erlotinib remaining the cost-effective option. Afatinib becomes more cost-
effective than erlotinib when its monthly drug cost decreased from $5,648 to below 
$3,802. ConClusions: Based on our analyses, we recommend erlotinib as the 
most cost-effective first-line treatment for EGFR-mutation positive NSCLC. Given 
the potentially similar relative efficacy between afatinib and erlotinib in the clini-
cal trials, cost-effectiveness analysis of afatinib versus erlotinib depends mostly 
on differences in drug and side-effects costs. Thus, afatinib may need to earn its 
share of the NSCLC market space with more competitive pricing.
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objeCtives: Acute promyelocytic leukemia (APL) constitutes a rare disease char-
acterized by a high mortality rate at early stage of treatment. Current first-line 
treatments consist of all-trans retinoic acid (ATRA), anthracyclines and conventional 
chemotherapy (CT). Although APL has currently a good prognosis, 20 to 30% of 
patients who achieved remission still relapse and are further resistant to the treat-
ment previously administrated. The objective of this study was to assess, from a 
Canadian perspective, the economic impact of arsenic trioxide (ATO) compared to 
ATRA+CT in the treatment of relapsed/refractory APL. Methods: The cost-effec-
tiveness of ATO compared to ATRA+CT in the treatment of relapsed/refractory APL 
was assessed over a lifetime horizon using a time-dependent Markov model. The 
model comprises five health states: induction, second remission, treatment failure 
or relapse, post-failure, and death. The length of each Markov cycle was one month 
for the first 24 months and one year thereafter. All patients started in the induction 
state and could move to other health states thereafter, according to the respective 
efficacy of each treatment. The model also takes into account the incidence of 
grade 3-4 adverse events reported in clinical trials. Utility or disutility values associ-
ated with each health state and adverse events were used to estimate the number 
of QALYs associated with each treatment. Analyses were conducted from both a 
Canadian Ministry of Health (MoH) and a societal perspective. Results: Compared 
with ATRA+CT, ATO was associated with incremental cost-effectiveness ratios of 
$18,380/QALY from a MoH perspective and $20,156/QALY from a societal perspec-
tive. Results of the probabilistic sensitivity analysis indicated that ATO remains a 
cost-effective strategy in 99.96% and 92.45% of the simulations, from a MoH and a 
societal perspective respectively. ConClusions: This economic evaluation sug-
gests that ATO is a cost-effective strategy compared to ATRA+CT in the treatment 
of relapsed/refractory APL in Canada.
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objeCtives: To examine the costs of hematologic malignancies (HMs) in relation 
to survival gains among Medicare beneficiaries. Methods: Using the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare datasets, we identified 99,721 
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objeCtives: Compare the cost effectiveness of 4 chemotherapy treatments for 
platinum-sensitive recurrent epithelial ovarian carcinoma (EOC). Methods: A 
Markov model was constructed using a hypothetical cohort of 500 women (median 
age 60) to compare 4 NCCN recommended treatment-regimens for platinum sensi-
tive recurrent EOC: carboplatin/paclitaxel (C/P); carboplatin/gemcitabine (C/G), C/G 
with bevacizumab (C/G+B); and carboplatin/pegylated liposomal doxorubicin (C/
PLD). These treatments were chosen as they are each supported by phase III trials. 
An indirect treatment comparison methodology was used to obtain evidence of the 
difference in treatment effects of each regimen. Progression free survival (PFS) and 
overall survival (OS) data were used for survival comparisons. The time horizon was 
thirty years. Cost calculations were based on data from Medicare and published 
literature, and were based on median cycle number from each trial. Published values 
of health utilities were used for QALY calculations. Cost effectiveness ratios (CER) 
were calculated for each regimen, and expressed as 3 incremental cost effectiveness 
ratios (ICER): additional month PFS, month OS, and QALY. Reported rates of grade 3/4 
toxicities from each trial were added to the cost of each treatment. Cost, survival, 
and toxicity rate were varied over a range for sensitivity analysis. Results: C/G 
was a cost-effective regimen. The cost for treating 1 woman with 6 cycles of C/G 
ranged from $1,140 (no toxicity) to $7,030 (toxicities at the reported rate). Treatment 
with C/G produced a dominant ICER of $236,318/month-PFS. For each PFS-month 
gained over the next most cost-effective option, over $200,000 was saved. C/G was 
the dominant strategy for OS, (ICER= $72,213/month OS). When adjusted for health 
utility, C/G was the dominant strategy (ICER of $20,443/QALY). ConClusions: C/G 
was a cost-effective regimen, resulting in a dominant ICER for PFS, OS, and QALY. C/G 
resulted in a savings compared to the next most cost effective regimen.
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objeCtives: Autologous stem cell transplantation (ASCT) is an integral part in the 
management of Multiple Myeloma (MM), the 2nd most common blood cancer. The 
collection of self stem cells – mobilization is required for ASCT. The optimal approach 
to procurement of stem cells remains debatable, with multiple competing clinical, 
cost and transplant-centre factors. In order to rationalize a preferred collection 
strategy we sought to perform a cost-effectiveness analysis from a Funder’s perspec-
tive of 4 common mobilization strategies used in Canada: Cyclophosphamide/G-CSF 
(Strategy 1), G-CSF alone (Strategy 2), Upfront-use of Plerixafor (Strategy 3), and “Just-
in-time” use of Plerixafor (Strategy 4). Methods: Clinical data was derived from 
published systematic reviews, randomized trials and observational studies. Further, 
a local audit was performed to evaluate external validity of the published data. 
Costing data for SC collection and adverse events were derived locally, The Ottawa 
Hospital. All unsuccessful 1st attempts with each strategy were assumed to be fol-
lowed by plerixafor re-mobilization. Probabilistic sensitivity analysis around costs 
and collection probabilities were varied simultaneously across their plausible range 
of values using Monte Carlo simulations (MCS). Results: Successful collection 
rates were 94.5%, 88.3%, 97.8% and 98.0% respectively for Strategies 1-4, with rates 
of adverse event of febrile neutropenia of 25.7%, 0%, 0% and 0%. Costs/patient were 
estimated as $8649, $9098, $17,309 and $13,119 respectively. Strategy 1 dominated 
strategy 2 in terms of cost and successful mobilization. The incremental cost per 
successful mobilization was $137,000 for strategy 4 vs. 1 and $1.6 million for strat-
egy 4 vs. 3. MCS found that the probability that strategy 4 was most successful was 
70.6%. Strategy 1 was least costly in 72.6% of simulations. ConClusions: Within 
the constraints of our model, our analyses suggest that Cyclophosphamide/G-CSF 
is a reasonable stem cell mobilization strategy in patients with myeloma requiring 
an ASCT, balancing costs and successful mobilization.
PCN95
brAf tArgEtEd thErAPiEs for thE trEAtmENt of mEtAstAtiC 
mElANomA: A Cost-EffECtivENEss ANAlysis
Shih V.1, ten Ham R.M.T.2, Bui C.T.1, Tran D.N.1, Wilson L.S.3
1University of California, San Francisco, San Francisco, CA, USA, 2Utrecht University, Utrecht, The 
Netherlands, 3University of California San Francisco, San Francisco, CA, USA
objeCtives: Melanoma is one of the fastest growing cancers worldwide and prog-
nosis is poor with metastases. In about 50% of melanoma patients the BRAFV600 
protein kinase mutation is present. Two BRAFV600 targeted therapies dabrafenib 
(Tafinlar®) and vemurafenib (Zelboraf®), have recently received U.S. approval to 
treat metastatic melanoma in BRAFV600patients. This study evaluated the cost-
effectiveness of BRAF inhibitors compared to traditional chemotherapy (dacar-
bazine). Methods: A Markov model was developed with three health states: stable 
disease, progression, and death and taking a lifetime societal perspective. Transition 
probabilities and clinical outcomes were derived from Phase III trials. Costs were 
in 2013 USD and derived from literature, national databases, and Medicare fees. 
Utilities for melanoma and other health states were obtained from studies con-
ducted on the general public. Deterministic and probabilistic sensitivity analyses 
were run to test the impact of uncertainties. Results: Cumulative cost of dacar-
bazine, dabrafenib and vemurafenib respectively were $15,282, $43,895, and $59,768. 
Monthly Drug costs were respectively $537, $7,570, and $10,807. Effectiveness of 
dacarbazine, vemurafenib and dabrafenib were 0.37, 0.5 and 0.52 LY, respectively and 
quality adjusted were 0.22, 0.35 and 0.39 QALY. The incremental cost-effectiveness 
ratio was $14,569 per QALY for dabrafenib compared to dacarbazine. Dabrafenib 
